MonoSol Rx Acquires U.S. Patent for Multifunctional Single Layer Film Drug Delivery Technology

Strengthens IP Leadership in Transmucosal Film Drug Delivery

        Print
| Source: MonoSol Rx

WARREN, N.J., Dec. 20, 2012 (GLOBE NEWSWIRE) -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced it has acquired U.S. Patent #8,241,661, entitled "Biocompatible Film with Variable Cross-Sectional Properties." The patent, issued by the United States Patent and Trademark Office on August 14, 2012, and related foreign filings were acquired from inventors Richard and Joseph Fuisz. This strategic patent provides for the non-uniform distribution of components in the thickness direction of a single layer biocompatible film, thereby allowing for a multifunctional film to be developed in a single layer.

A. Mark Schobel, Co-President and Chief Executive Officer of MonoSol Rx, stated, "The addition of this patent to our IP portfolio reinforces MonoSol Rx as a leader and innovator in pharmaceutical film technology, and strengthens our proprietary film drug development capabilities from a compositional, method of manufacture, and drug performance perspective. This patent will be a significant IP asset to MonoSol Rx as we progress with our unidirectional transmucosal film drug delivery products and for those pharmaceutical companies who partner with us.  This patented technology will also allow for the highly cost effective manufacturing of single layer multifunctional films where, currently, two or more film layers are necessary. Richard and Joseph Fuisz are leaders in the drug delivery space, and we are pleased to be the recipients of this ground-breaking technology.  We are particularly pleased that the patent life for U.S. Patent #8,241,661 will extend well into 2031."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence. For press releases and other company information visit www.monosolrx.com.

* PharmFilm is a registered trademark of MonoSol Rx.      

The Ruth Group (on behalf of MonoSol Rx)
Carol Ruth/Stephanie Carrington
The Ruth Group
646.536.7000